All studies
Endocrinology · EHR · China
Zhao 2026
Type 2 diabetes
QBA performedITTSuperiorityAcademia, Industry2/5 disclosures
Comparisons
1
In the analysis
0
1 withheld
Target trials
1
Emulations reported
1
2 treatments
Design and methods
- Estimand
- ITT
- Design hypothesis
- Superiority
- Matching / weighting
- 1:1 propensity-score matching
- Analysis method
- Matched Cox proportional hazards model
- Missing data
- Complete case
- DAG
- No
- QBA
- Yes
Data and sample
- Data type
- EHR
- Data sources
- 1
- Geography
- China
- Eligible sample
- 17772
- Treated
- 8886
- Control
- 8886
- Emulations
- 1
- Treatments compared
- 2
Transparency
- Protocol
- No pre-registration
- Preprint
- No preprint
- Data availability
- Unavailable
- Code availability
- Unavailable
- Conflicts of interest
- Declared: Industry
- COI institutions
- Relationships listed in the report
- Funding
- Declared: Public, Private
- Funders
- Funding listed in the report
The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.
Provenance
- Review key
- 2026_Zhao_LEADER
- DOI
- 10.3389/fendo.2026.1777954
- Affiliations
- Chinese academic institutions and LinkDoc data platform
- Sector
- Academia, Industry
- Target trials (study level)
- LEADER
- Registration
- NCT01179048